Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
I want you to honestly evaluate your own situation when considering whether Patchie aligns with your goals
Those who may have trouble losing weight through traditional methods alone
Rhythms lead asset, IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Setmelanotide Indication In In the Limitations of Use Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity
fits 0.5 mL syringe 75 mg draw 0.75 mL / 75 units
